Codexis API Approved

Codexis (Redwood City, CA) says that the U.S. FDA has approved a new process co-developed by Codexis for the manufacture of sitagliptin, the active pharmaceutical ingredient (API) in Merck & Co.’s (Whitehouse Station, NJ) Januvia, a treatment for type 2 diabetes. The approved process has the potential to increase the yield of sitagliptin, while significantly decreasing waste byproducts, Codexis says. Codexis develops industrial enzymes to enable the production of biofuels, bio-based chemicals, and pharmaceutical...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers